Serveur d'exploration sur l'opéra

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies

Identifieur interne : 002041 ( Main/Exploration ); précédent : 002040; suivant : 002042

The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies

Auteurs : N J Talley [Australie] ; K. Lauritsen [Danemark]

Source :

RBID : ISTEX:F39853DD66D60490DBFBD5158A6FEA551AB007D9

Descripteurs français

English descriptors

Abstract

Dyspepsia is a common condition in the general population but data are lacking on the benefits of effective acid inhibition with proton pump inhibitors in functional dyspepsia. The results of the large, randomised, double blind clinical trials, BOND and OPERA, the Scandinavian PILOT study, and a follow up study, ENCORE, are reviewed. BOND, OPERA, and PILOT aimed to address the question of whether effective acid inhibition with the proton pump inhibitor omeprazole relieves symptoms in patients with functional dyspepsia. ENCORE followed on from this, addressing the consequences of relieving symptoms in patients with functional dyspepsia once they are off therapy.

Url:
DOI: 10.1136/gut.50.suppl_4.iv36


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies</title>
<author>
<name sortKey="Talley, N J" sort="Talley, N J" uniqKey="Talley N" first="N J" last="Talley">N J Talley</name>
</author>
<author>
<name sortKey="Lauritsen, K" sort="Lauritsen, K" uniqKey="Lauritsen K" first="K" last="Lauritsen">K. Lauritsen</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:F39853DD66D60490DBFBD5158A6FEA551AB007D9</idno>
<date when="2002" year="2002">2002</date>
<idno type="doi">10.1136/gut.50.suppl_4.iv36</idno>
<idno type="url">https://api.istex.fr/document/F39853DD66D60490DBFBD5158A6FEA551AB007D9/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000200</idno>
<idno type="wicri:Area/Istex/Curation">000200</idno>
<idno type="wicri:Area/Istex/Checkpoint">000966</idno>
<idno type="wicri:doubleKey">0017-5749:2002:Talley N:the:potential:role</idno>
<idno type="wicri:Area/Main/Merge">002119</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:02-0347327</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000596</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000086</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000505</idno>
<idno type="wicri:doubleKey">0017-5749:2002:Talley N:the:potential:role</idno>
<idno type="wicri:Area/Main/Merge">002196</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11953346</idno>
<idno type="wicri:Area/PubMed/Corpus">000621</idno>
<idno type="wicri:Area/PubMed/Curation">000621</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000569</idno>
<idno type="wicri:Area/Ncbi/Merge">000099</idno>
<idno type="wicri:Area/Ncbi/Curation">000099</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000099</idno>
<idno type="wicri:doubleKey">0017-5749:2002:Talley N:the:potential:role</idno>
<idno type="wicri:Area/Main/Merge">002075</idno>
<idno type="wicri:Area/Main/Curation">002041</idno>
<idno type="wicri:Area/Main/Exploration">002041</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies</title>
<author>
<name sortKey="Talley, N J" sort="Talley, N J" uniqKey="Talley N" first="N J" last="Talley">N J Talley</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Medicine, University of Sydney, Nepean Hospital, Penrith</wicri:regionArea>
<wicri:noRegion>Penrith</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Lauritsen, K" sort="Lauritsen, K" uniqKey="Lauritsen K" first="K" last="Lauritsen">K. Lauritsen</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Danemark</country>
<wicri:regionArea>Department of Medical Gastroenterology, Odense University Hospital, Odense</wicri:regionArea>
<wicri:noRegion>Odense</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Gut</title>
<title level="j" type="abbrev">Gut</title>
<idno type="ISSN">0017-5749</idno>
<idno type="eISSN">1468-3288</idno>
<imprint>
<publisher>BMJ Publishing Group Ltd and British Society of Gastroenterology</publisher>
<date type="published" when="2002-05">2002-05</date>
<biblScope unit="volume">50</biblScope>
<biblScope unit="supplement">suppl 4</biblScope>
<biblScope unit="page" from="iv36">iv36</biblScope>
</imprint>
<idno type="ISSN">0017-5749</idno>
</series>
<idno type="istex">F39853DD66D60490DBFBD5158A6FEA551AB007D9</idno>
<idno type="DOI">10.1136/gut.50.suppl_4.iv36</idno>
<idno type="href">gutjnl-50-iv36.pdf</idno>
<idno type="PMID">11953346</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0017-5749</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Anti-Ulcer Agents (therapeutic use)</term>
<term>Antiacid</term>
<term>Australia</term>
<term>Benzimidazole derivatives</term>
<term>Biological activity</term>
<term>Chemotherapy</term>
<term>Clinical trial</term>
<term>Double blind study</term>
<term>Double-Blind Method</term>
<term>Dysfunction</term>
<term>Dyspepsia</term>
<term>Dyspepsia (drug therapy)</term>
<term>Female</term>
<term>GORD, gastro-oesophageal reflux disease</term>
<term>GSRS, gastrointestinal symptom rating scale</term>
<term>Helicobacter pylori</term>
<term>Human</term>
<term>Humans</term>
<term>ITT, intention to treat</term>
<term>MBS, most bothersome symptom</term>
<term>Male</term>
<term>Omeprazole</term>
<term>Omeprazole (therapeutic use)</term>
<term>PGWB, psychological general well being</term>
<term>Proton pump inhibitor</term>
<term>Randomization</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Treatment Outcome</term>
<term>dysmotility</term>
<term>functional dyspepsia</term>
<term>omeprazole</term>
<term>reflux</term>
<term>ulcer</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Anti-Ulcer Agents</term>
<term>Omeprazole</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Dyspepsia</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Double-Blind Method</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Activité biologique</term>
<term>Antiacide</term>
<term>Australie</term>
<term>Benzimidazole dérivé</term>
<term>Chimiothérapie</term>
<term>Dyspepsie</term>
<term>Essai clinique</term>
<term>Etude double insu</term>
<term>Homme</term>
<term>Inhibiteur pompe proton</term>
<term>Oméprazole</term>
<term>Randomisation</term>
<term>Trouble fonctionnel</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr">
<term>Australie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Homme</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Dyspepsia is a common condition in the general population but data are lacking on the benefits of effective acid inhibition with proton pump inhibitors in functional dyspepsia. The results of the large, randomised, double blind clinical trials, BOND and OPERA, the Scandinavian PILOT study, and a follow up study, ENCORE, are reviewed. BOND, OPERA, and PILOT aimed to address the question of whether effective acid inhibition with the proton pump inhibitor omeprazole relieves symptoms in patients with functional dyspepsia. ENCORE followed on from this, addressing the consequences of relieving symptoms in patients with functional dyspepsia once they are off therapy.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Australie</li>
<li>Danemark</li>
</country>
</list>
<tree>
<country name="Australie">
<noRegion>
<name sortKey="Talley, N J" sort="Talley, N J" uniqKey="Talley N" first="N J" last="Talley">N J Talley</name>
</noRegion>
</country>
<country name="Danemark">
<noRegion>
<name sortKey="Lauritsen, K" sort="Lauritsen, K" uniqKey="Lauritsen K" first="K" last="Lauritsen">K. Lauritsen</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002041 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002041 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:F39853DD66D60490DBFBD5158A6FEA551AB007D9
   |texte=   The potential role of acid suppression in functional dyspepsia: the BOND, OPERA, PILOT, and ENCORE studies
}}

Wicri

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Oct 8 06:48:41 2020